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setting. The patient’s baseline inulin clearance, measured on
day 0 of her GCRC stay, was 22 mL/min/1.73 m2 (Fig. 1). She
received IGF-I (100 mg/kg subcutaneously twice daily) during
days 4 through 7. Concomitant with IGF-I administration, her
levels of circulating IGF-I were transiently elevated. The inulin
clearance increased to 39 mL/min/1.73 m2 on day 7. By day 25,
IGF-I levels and inulin clearance had returned to baseline.
When last seen in the Renal Clinic, 13 months after her GCRC
admission, the BUN was 58 mg/dL and serum creatinine was
14.2 mg/dL; creatinine clearance was 10 mL/min. The next day
she received a renal transplant. Six years later, it is functioning
well and her serum creatinine is 2.1 mg/dL.
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CASE PRESENTATION Dr. Marc R. Hammerman (Director, Renal Division,
A 17-year-old girl was transferred to Barnes-Jewish Hospital and George M. O’Brien Kidney and Urological Diseases
from an emergency room outside the Washington University Center; and Chromalloy Professor of Renal Diseases incomplex. Ten days previously, she had developed fever and
Medicine; Washington University School of Medicine, St.had experienced diffuse abdominal pain, nausea, and vomiting.
Louis, Missouri, USA): Early in the study of vertebrateSubsequently, she developed flank pain and dysuria. The pa-
tient had a history of chronic renal insufficiency secondary to embryology, observers noticed that animals vastly differ-
recurrent pyelonephritis. Her first urinary tract infection was ent as adults are similar in structure and appearance as
diagnosed when she was six months old; urethral stenosis was embryos. Further, the embryos of “higher” vertebratesdiscovered at that time. An intravenous pyelogram performed
often exhibit conditions similar to those seen in the adultssix months later showed reflux and tortuous ureters. Urethral
of “lower” groups. On the basis of such observations,dilation was carried out. Between the ages of six months and
10 years, she had 10 urinary tract infections. the German biologist Ernst Haeckel proposed his “bio-
At the time of admission to Barnes-Jewish Hospital, the genetic law”: Ontogeny recapitulates phylogeny. Haeck-
patient’s serum creatinine was 4.3 mg/dL and her BUN was el’s dictum held that the biologic history of an individual73 mg/dL. Urine cultures grew Escherichia coli and the patient
must, in abbreviated form, repeat the biologic develop-was treated with antibiotics. After responding well to therapy,
ment of its ancestors [1, 2].she was discharged to be followed as an outpatient by the
Washington University Renal Division. The patient’s creati- It is now understood that the “biogenetic law” repre-
nine clearance measured just prior to discharge was 27 mL/ sents only a half-truth. Much worse, in the light of Haeck-
min.
el’s advocacy for eugenics and social Darwinism, theEight months following discharge, the patient was admitted
motives behind formulation of the “biogenetic dictum”to the General Clinical Research Center (GCRC) at Washing-
ton University. To our knowledge, she was the first patient have been questioned [2]. Whatever his motives, Haeckel
with chronic renal failure ever to receive recombinant human was indeed half correct, in that ontogeny does appear
insulin-like growth factor (IGF-I) to ascertain whether the to recapitulate phylogeny. This similarity is likely due
glomerular filtration rate can be increased by IGF-I in this
to the fact that genes can persist in the genome for
millions of years after their utility has disappeared [1].
The development of the vertebrate kidney has beenThe Nephrology Forum is funded in part by grants from Astra Pharma-
ceuticals; Amgen, Incorporated; Merck & Co., Incorporated; Dialysis cited as the most compelling evidence for the validity of
Clinic, Incorporated, and R & D Laboratories. Haeckel’s dictum [1]. Three successive renal structures
develop during embryogenesis; these structures are theKey words: renal embryology, insulin-like growth factor-I, xenotrans-
plantation, acute renal failure, chronic renal failure. pronephros, mesonephros, and metanephros. It was
thought originally that these were three distinct kidneysÓ 2000 by the International Society of Nephrology
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Fig. 1. Inulin clearance (vertical bars) and se-
rum insulin-like growth factor-I (IGF-I) levels
(d) measured over time in a patient with
chronic renal failure. The time of administra-
tion of IGF-I is indicated by the closed hori-
zontal bar. Reprinted with permission from
the American Physiological Society [33].
that succeeded one another in their “phylogeny” as well cused to think critically about the evolution of the kidney
and about renal development. Such thinking has led toas in their “ontogeny.” However, such a thought, like the
“biogenetic law” itself, is a half-truth. The pronephros, insights into potentially novel means of therapy for renal
disease. Perhaps, in the case of the “biogenetic law,”mesonephros, and metanephros, all of which derive from
the same band of intermediate mesoderm, are best con- half a truth is better than none. In this Forum, I plan to
discuss how thinking about the evolution of the kidneysidered as a single organ, or holonephros [3–7].
It is possible to distinguish a pronephros from a meso- and about renal development, and about the growth
factors that participate in development, has led to in-nephros only in those classes of vertebrates that lack
an amnion during their development (anamniotes), and sights into the treatment of acute and chronic renal fail-
ure and into a novel means of renal transplantation.then only in larval stages. In some larval anamniotes,
the anterior tubules of the holonephros appear early,
Acute renal failureshortly after the first somites are differentiated, and a
duct is formed that empties into the cloaca. Only in such The nephron, the functional unit of the vertebrate
cases is it accurate to speak of a distinct pronephros [3]. kidney, consists in adults of several functional compo-
While it is possible that a pronephros-like structure nents: the corpuscle (comprising the vascular loop of the
served alone as the kidney in adult forms of a long- glomerulus and the glomerular capsule), the nephrocele,
extinct ancestor vertebrate, there is no evidence that it the nephrostome, the tubule, and the nephric duct (Fig.
does so today. The term pronephros is best used to de- 2) [4]. Other patterns are found more often in embryos,
scribe the kidney in larval anamniotes and to describe particularly in the first units developed, and more often
a portion of the kidney in a few adult teleosts in which in lower vertebrate classes. These latter patterns always
a distinct pronephros can persist into maturity in addition have a ciliated peritoneal funnel opening from the coe-
to a meso-metanephros (opisthonephros) [3]. Therefore, lomic cavity into the tubule. A typical glomerulus is
even in the case of the kidney, it is probably more accu- sometimes present, but in some cases it lies in the coe-
rate to think in terms of ontogeny recapitulating proto- lomic cavity; in other cases, it is absent altogether [4, 5].
phylogeny (defined as the adult form of a long-extinct It is possible that the renal tubules originally served to
drain wastes and excess fluid from the coelom (a sort ofancestor vertebrate) rather than ontogeny recapitulating
phylogeny. peritoneal dialysis in situ). The formation of a glomerulus
and glomerular filtration of blood might have been anIs there utility in nephrology for the half-truth that
ontogeny recapitulates phylogeny? I believe that there “afterthought” [5].
The vertebrate kidney serves a variety of functions,is, because in considering Haeckel’s dictum we are fo-
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and to reduce the risk of medullary injury during hypo-
perfusion. This reduction in risk can be accomplished by
increasing medullary blood flow or decreasing transport
work to preserve oxygen sufficiency [8]. Homeostasis,
however, can be rendered insufficient in all mammals by
excessive blood loss or dehydration or by exposure to
renal toxins. The development of acute renal failure
(ARF) would result in death if the vulnerable parts of
the kidney were incapable of regeneration. However,
ARF usually is reversible in humans and in other mam-
mals, provided that fluid and solute balance can be main-
tained until spontaneous renal repair takes place [9].
The development of a mechanism for repairing the
damaged kidney probably provided early mammals with
Fig. 2. The vertebrate nephron. Abbreviations are: Ca, capsule; G,
a survival advantage relative to their “cousins,” who didglomerulus; Nc, nephrocele; T, tubule; ND, nephric duct; Ns, nephro-
stome; PF, peritoneal funnel. Reprinted with permission from Cam- not have such a mechanism. A thorough understanding
bridge University Press [4]. of the repair process could yield insights into novel thera-
pies, such as exogenous growth factors, for enhancing
renal regeneration in patients with ARF. The rationale
for the use of exogenous growth factors as therapeuticamong them the maintenance of salt and water balance.
agents in ARF comes from observations in animal mod-Maintaining that balance presents the vertebrate kidney
els indicating that growth factors enhance renal repairwith a different challenge depending upon the environ-
[9]. We have concentrated our efforts on the use of IGF-Iment in which its owner lives. Differences in the structure
for the following reasons: (1) The proximal tubule cellof the nephron among classes of vertebrates reflect dif-
has receptors for, and is responsive to, IGF-I [9–13]; (2)ferent ways in which the challenge is met. Amphibians
IGF-I, normally expressed in the renal collecting ductand freshwater fish live in an environment that is hypo-
[10], is transiently expressed in regenerating proximal
tonic relative to their body fluids. For them, the challenge
tubule cells beginning two to three days following acute
is to avoid “death by dilution.” The nephrons of these
renal injury in rats [14, 15]; and (3) IGF-I can be safely
vertebrate classes have large corpuscles that can filter administered to humans [9].
and eliminate large quantities of solute-free water. In The rat is a useful experimental model for ARF in
contrast, saltwater fish, living in a hypertonic milieu, humans [9]. Ischemic renal injury in the rat damages the
are subject to “death by dehydration”; the nephrons most distal segment (S3) of the proximal tubule, whichof saltwater fish have relatively small glomeruli. Water is vulnerable to hypoxemia. Recovery depends on the
conservation is effected by low rates of output [5]. ability of the tubular cells to regenerate and reline the
All land vertebrates must conserve water. Reptiles damaged areas along the nephron [8, 9]. We have shown
have met this challenge in a manner similar to that of in rat studies that IGF-I administered prior to, immedi-
saltwater fish. Reptiles’ nephrons have relatively small ately after, or 24 hours after acute ischemic injury accel-
glomeruli. In contrast, the nephrons of mammals and erates the recovery of normal renal function and the
birds have relatively large glomeruli that effect high wa- regeneration of damaged proximal tubular epithelium,
ter throughput. Conservation of solute-free water in and reduces mortality rates [9, 16, 17]. Similar findings
these classes of vertebrates is carried out by a novel were reported by many others using animal models of
structure, the loop of Henle [5]. ischemic and toxic injury [18–23].
The kidney is one of the best-oxygenated organs in Several explanations have been proposed for the effec-
the human body. However, the bulk of this blood supply tiveness of IGF-I when administered following ischemic
is delivered to the cortex. The poorly oxygenated me- renal injury in rats. First, IGF-I increases glomerular
dulla, a characteristic of all mammalian kidneys, is a filtration rate via a direct action on the glomerular vascu-
requirement for the efficient urinary concentrating lature. In rats, infusion of IGF-I decreases renal glomeru-
mechanism provided by the loop of Henle and counter- lar afferent and efferent arteriolar resistances and in-
current exchanger. Medullary hypoxemia, however, ren- creases the glomerular ultrafiltration coefficient [13, 24].
ders the kidney particularly vulnerable to ischemic in- The ability of IGF-I to dilate preglomerular vessels prob-
jury. Such vulnerability is a trade-off for the kidney’s ably is mediated via local production of nitric oxide and
ability to conserve solute-free water [8]. vasodilatory prostaglandins [25]. An increase in the glo-
A coordinated homeostatic mechanism is present merular filtration rate induced by IGF-I could alter the
course of ARF, possibly by limiting the extent of injurywithin the kidney to allow efficient urinary concentration
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acute renal injury cannot explain the action of IGF-I
pretreatment to accelerate recovery following injury.
Rather, the efficacy of IGF-I when administered prior
to the induction of acute renal injury could reflect the
phenomenon of “preconditioning.” The phenomenon of
preconditioning is not unique to the kidney and has been
most studied experimentally in the myocardium. Ytrehus
et al have proposed that a short period of ischemia pro-
tects the myocardium by “preactivating” genes that are
important in protecting it from subsequent, more sus-
tained ischemic injury [31]. The molecular basis for myo-
cardial preconditioning is undefined. Like the heart, the
kidney can be protected from ischemia by a prior ische-Fig. 3. Creatinine clearance in patients who received IGF-I (r) or
placebo (h) post surgery. Data are presented as change in clearance mic episode. Rats that are at the height of acute renal
(GFR) from baseline 6 SE (*P , 0.05). Reprinted with permission failure following ischemic injury are relatively resistantfrom the American Physiological Society [29].
to subsequent ischemic insults [32].
No “preactivated” gene that protects the ischemic kid-
ney from subsequent injury has been definitively identi-
due to obstruction of tubules by cellular debris. Second, fied. However, one potential gene, the expression of
IGF-I reduces protein breakdown and exerts a general- which is enhanced in the kidney at the site of tubular
ized anabolic action [26]. This action attenuates weight regeneration following the peak of renal dysfunction, is
loss in the setting of the catabolism that accompanies the gene for IGF-I [14, 15]. One could argue, as I do,
acute ischemic injury in the rat [17, 18]. Third, although that administration of IGF-I to rats prior to ischemic
IGF-I has little or no mitogenic action on cells in the injury could substitute for its renal “preactivation” and
proximal tubule when administered to normal adult rats might ameliorate the subsequent renal injury.
[27], it does enhance DNA synthesis in regenerating
Chronic renal failureproximal tubule cells following ischemia/reperfusion in-
jury [28]. The potential for the use of IGF-I as a therapeutic
The successful use of IGF-I in rats has led to clinical agent for enhancing renal function in the setting of
trials in humans. We showed that, in patients undergoing chronic renal failure is based on clinical and experimen-
surgery during which blood flow to the kidneys is inter- tal observations relating to the action of growth hormone
rupted, IGF-I administered postoperatively eliminates on the kidney [9–11, 33]. In short, conditions of growth
the fall in glomerular filtration rate that occurs in pla- hormone deficiency in humans and experimental animals
cebo-treated subjects (Fig. 3) [29]. The incidence of ARF are associated with a reduction of renal size, glomerular
in our study population was too low to permit any conclu- filtration rate, and renal plasma flow; states of growth
sions regarding IGF-I’s ability to ameliorate the course hormone excess are associated with an increase in renal
of postoperative ARF. However, IGF-I was well toler- size and increased glomerular filtration rate and renal
ated and significantly enhanced glomerular filtration plasma flow [33]. The ability of growth hormone to in-
rates postoperatively. A second trial conducted to test crease renal size, glomerular filtration rate, and renal
the ability of IGF-I in established ARF was terminated plasma flow is not mediated by growth hormone directly,
after an interim analysis demonstrated no beneficial ef- but rather by IGF-I. One mechanism by which IGF-I
fect. It was suggested that the severity of systemic illness, exerts these actions is via rapid alterations of glomerular
heterogeneity of causes of ARF (surgery, trauma, hypo- hemodynamics; these changes might relate to the role
tension, sepsis, or drugs), or a delay in starting IGF-I IGF-I plays in renal repair of post-ischemic injury. Al-
therapy after the onset of ARF might have contributed though IGF-I dilates preglomerular vessels, renal auto-
to the negative outcome [30]. regulatory capacity is not reduced by the growth factor
The explanation for the effectiveness of IGF-I when [25]. The preserved renal autoregulatory capacity is an
administered prior to the induction of ischemic injury in important consideration relating to the safety of IGF-I
rats (IGF-I pretreatment) [17] is less clear than for its administration in patients with ARF and end-stage renal
effectiveness following injury. Rats pretreated with disease (ESRD).
IGF-I do not manifest elevated rates of glomerular fil- The recognition that growth hormone can increase
tration or renal plasma flow, increased body weights, or glomerular filtration rate prompted the suggestion de-
increased DNA synthesis in the renal cortex compared cades ago that it be used as a therapeutic agent in the
to vehicle-pretreated animals [17]. Therefore, a differ- setting of chronic renal failure [34]. However, the defini-
tive testing of its efficacy required the development andence in one or more of these parameters prior to the
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availability of recombinant preparations. But early inves-
tigations into its utility were disappointing. For example,
Haffner et al found that growth hormone had no effect
on glomerular filtration rate in seven patients with
chronic renal insufficiency even though it was anabolic
and the identical dosage increased the glomerular filtra-
tion rate in individuals with normal renal function [35].
Thus, Haffner et al suggested that the uremic state is
one of relative renal resistance to the actions of growth
hormone [35].
Resistance to IGF-I in uremia [reviewed by Ding et
al, 36], was first suggested by the observation that IGF-I
bioactivity in the serum of patients with ESRD is less
Fig. 4. Inulin clearance over time in five patients receiving IGF-I.than that predicted by IGF-I immunoactivity. Moreover,
Dashed line shows times during which IGF-I was administered. Datathe ability of IGF-I to lower levels of amino acids, insulin, are expressed as mean 6 SE. Differences between day 0 and other
and C-peptide was found to be blunted in patients under- days were examined by Dunnett’s multiple comparisons test (*P ,
0.05, **P , 0.01). Reproduced with permission from the Americangoing hemodialysis or peritoneal dialysis compared to
Physiological Society [39].controls [36]. In addition, the ability of IGF-I to stimulate
protein synthesis and inhibit protein degradation in skel-
etal muscle isolated from rats with reduced functional
renal mass is reduced compared to its action in muscle 4 to 18 months after beginning IGF-I therapy. Our study
shows that IGF-I sustains improvement of renal functionfrom control rats; this finding thus is consistent with
IGF-I resistance in this experimental model of ESRD in patients with severe chronic renal failure and is well
tolerated. Inulin clearances in patients receiving IGF-I[36]. Similarly, we showed that the increase in inulin
clearance that follows the administration of either are comparable to those generally achieved by dialysis
(Fig. 4) [39].growth hormone or IGF-I to normal rats is not observed
following administration of the same doses of peptides
Renal transplantationto rats with reduced renal function [37].
To answer the question directly as to whether humans The metanephric kidneys originate during the fifth
week of gestation in humans, and during day 12 of embry-with ESRD respond to the renal effects of IGF-I, we
administered IGF-I to individuals whose baseline inulin onic rat development [4]. After renal development is
complete, no new nephrons are formed under any condi-clearances were so low that dialysis was contemplated;
we evaluated the effects of IGF-I on both inulin and p- tions. The loss of renal functional mass that occurs fol-
lowing insults to the adult kidney is compensated inaminohippurate (PAH) clearances. IGF-I, administered
by subcutaneous injection (100 mg/kg twice daily), in- the short term by hypertrophy and hyperfunction of the
remaining nephrons [38]. However, these compensatorycreased both clearances over a four-day period. How-
ever, at this dose level, patients became refractory to its changes are often transient and under some circum-
stances maladaptive in that they can lead to further lossaction within one to two weeks, and the incidence of
serious side effects (Bell’s palsy, pericardial friction rub, of renal function [reviewed in 38, 39].
End-stage chronic renal failure afflicts more thangingival swelling) was high [38]. We assessed the ability
of a lower IGF-I dose to reduce side effects, and we 300,000 individuals in the United States, most of whom
are treated with dialysis, a treatment with considerableused intermittent administration in an effort to eliminate
refractoriness. To this end, patients with ESRD (inulin morbidity [40], or renal allotransplantation, which is lim-
ited by the number of organs available [41]. One possibleclearance, 5.6 to 15.4 mL/min/1.73 m2) were enrolled
in an open-label 24-day trial or a 31-day double-blind, solution to the lack of organ availability is the use of
renal xenografts. The clinical renal xenografts performedplacebo-controlled, randomized trial. Patients received
subcutaneous IGF-I, 50 mg/kg/day, or placebo on an in- to date have utilized primate donors, because the closer
species are phylogenetically, the more easily xenograftstermittent schedule of four days receiving the agents
followed by three days not receiving them. Treatment are accepted [42]. The clinical experience with the use
of primates as kidney donors dates from the 1960s. How-with IGF-I significantly increased glomerular filtration
rate during the third and fourth weeks of therapy both ever, the results of xenografting of kidneys have been
unsatisfactory, and this technique has remained an ex-in open-label and double-blind studies. As anticipated,
the placebo had no effect. No patient required discontin- perimental one [42, 43].
A second possible solution to the lack of organ avail-uation of the drug secondary to side effects. Several
patients studied prospectively remained off dialysis for ability is the transplantation of developing kidneys
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(metanephric allografts or xenografts). The allotrans- phocytes were observed (not shown), but there was no
lymphocytic infiltration of tubular or vascular elements.plantation of developing metanephroi into adult animals
has been performed by several investigators [44–49]. In seven rats that had received transplanted meta-
nephroi six weeks previously and in which unilateralFour theoretical reasons explain why the transplantation
of allograft or xenograft metanephroi into adult animals nephrectomy also had been performed, the ureter of a
transplanted metanephros was anastomosed to the ure-might be advantageous relative to the transplantation of
kidneys. First, for several days following its formation, ter of the kidney that was removed. Four weeks later,
the contralateral kidney also was removed. Followingthe metanephros has no vasculature [4] and therefore
contains few or no antigen-presenting cells derived from removal of both native kidneys, inulin clearances were
measured. The plasma creatinine level, measured follow-the circulation. Depletion of antigen-presenting cells (or
passenger lymphocytes) would be expected to render ing removal of all native renal tissue, was 1.3 6 0.06
mg/dL, approximately three times normal. Inulin andallograft or xenograft metanephroi less immunogenic
[42, 43]. Second, the transplanted metanephros becomes creatinine clearances were 0.11 6 0.02 and 0.65 6 0.18
mL/min/100 g body weight, respectively (mean 6 SE).a chimeric organ in that it is vascularized in part by blood
vessels originating from the host kidney [44]. Hyperacute The mean body weight of the rats was 238 6 3.0 g. The
weight of the metanephroi was 71 6 15 mg. The volumerejection of xenografts that is initiated by circulating
preformed natural antibodies that activate complement of urine collected during three hours was 49 6 13 mL.
Inulin and creatinine clearance in a group of five normalafter binding to glycoprotein antigens on endothelial cell
surfaces [42, 43] is likely to be circumvented to the extent rats of similar size was 0.92 6 0.14 and 0.84 6 0.12 mL/
min/100 g, respectively [49].that the transplanted organ is supplied by host vessels.
Third, the expression of class-II major histocompatibility Three rats underwent unilateral nephrectomy and par-
tial contralateral infarction at the time of metanephrosheterodimers on non-lymphoid, proximal tubule cells
within the metanephros possibly serves as an extrathymic implantation 10 weeks prior to measurement. Weights
of transplanted metanephroi were increased more thanmechanism for the maintenance of immune tolerance
[43]. Fourth, the migration of host T-cells through neona- twofold, and inulin clearances expressed per gram of
renal weight were increased more than 12-fold comparedtal (embryonic) tissues might induce tolerance [50].
The possibility that renal function can be enhanced to values obtained in rats that underwent unilateral ne-
phrectomy without partial contralateral renal infarction.by the addition of functioning nephrons via transplanta-
tion of metanephric sections intrarenally [44–47] or in Urine volumes also were significantly increased [49].
These observations indicate that the stimulus that resultsthe abdominal wall [48] has been explored. These studies
suggest that transplantation of sectioned metanephroi in compensatory renal growth following reduction of
renal mass also might enhance the growth and develop-into kidneys of adult hosts is possible but is complicated
by graft rejection within a few days. Using an intra- ment of transplanted metanephroi [49].
Transplanted metanephroi grow in a number of sites,abdominal approach, we implanted whole metanephroi
from Sprague-Dawley rat embryos on embryonic day 15 including beneath the renal capsule [44–47, 49, 51], in
the abdominal wall [48], and into the immunologicallyinto kidneys of outbred adult rats. These metanephroi
contained segments of ureteric bud and condensing privileged anterior chamber of the eye [45, 52]. During
mammalian embryogenesis, nephric tubules of the pro-metanephric blastema, but no glomeruli [49]. We also
implanted metanephroi into the omentum of six-week- nephros and mesonephros open medially into the intra-
embryonic coelom for a time during their developmentold rats which immediately thereafter underwent unilat-
eral nephrectomy [49]. Six weeks later, we removed the (Fig. 2). This observation may have relevance for trans-
plantation into the omentum. One side or the other ofremaining renal tissue (both native kidney and trans-
plant). When metanephroi transplanted into the omen- the omental membrane may be particularly supportive
of renal organogenesis. In contrast to the relative ab-tum were examined post transplantation, they had as-
sumed a kidney-like shape in situ (Fig. 5A) and were sence of rejection in transplanted metanephroi, adult
kidneys transplanted from one Sprague-Dawley rat toapproximately one-third the diameter of the native kid-
neys (Fig. 5B). The metanephroi transplanted with ure- another in the absence of immunosuppression undergo
rejection; the renal architecture is obliterated by an in-teric buds attached had intact ureters (Fig. 5C). Sections
of transplanted metanephroi were prepared and stained tense mononuclear cell infiltrate, and the tubules are
destroyed by seven days post transplantation [49].with hematoxylin and eosin. Both cortical and medullary
tissue was present (Fig. 5D). Cortices had well-developed To ascertain whether metanephroi from a mouse can
be transplanted into a rat, we obtained embryonic dayglomeruli containing red blood cells, proximal tubules
with well-developed brush-border membranes, and dis- 14 metanephroi from National Institutes of Health Swiss
mouse embryos (Harlan, Indianapolis, IN) and im-tal tubules (Fig. 5E). Medullas contained well-developed
collecting ducts (Fig. 5F). Rare accumulations of lym- planted them into kidneys of Sprague-Dawley rats that
Nephrology Forum: Recapitulation in nephrology748
Fig. 5. Rat metanephroi six weeks after
transplantation into the omentum of unilater-
ally nephrectomized host rats (A, B, C) and
photomicrographs of hematoxylin- and eosin-
stained sections of metanephroi (D, E, F). (A)
Developed metanephros in abdominal cavity
(m). (B) Developed metanephros after re-
moval from abdominal cavity compared to na-
tive kidney. (C) Developed metanephros, ure-
ter (u) shown. (D) Section of developed
metanephros with ureter. (E) Section of cor-
tex from developed metanephros: glomerulus
(g), proximal tubule (p), brush border (arrow-
head), and distal tubule (d) [51]. (F) Section
of medulla from developed metanephros: col-
lecting duct (cd) is shown. Magnifications for
A–D are shown (B), and for E–F (E). Re-
printed with permission from the Interna-
tional Society of Nephrology [49].
had undergone unilateral nephrectomy and partial con- other [49] or from mouse to rat [51] are rapidly rejected
suggests that metanephroi are less immunogenic thantralateral renal infarction. Some rats were treated with
cyclosporine A (CsA; 5 mg/kg injected subcutaneously adult kidney. Transplantation of xenograft metanephroi
once per day). Four weeks post transplantation, all that (perhaps pig to human) followed by ureteroureteros-
remained of the metanephroi in the kidneys of the non- tomy could represent a new therapeutic approach to the
CsA-treated rats was fibrotic tissue (Fig. 6A). However, treatment of chronic renal failure in humans.
metanephroi grew, became vascularized, and developed
when transplanted into the CsA-treated hosts. Some tu-
QUESTIONS AND ANSWERSbules were calcified (Fig. 6B). Glomeruli in the host rat
Dr. Nicolaos E. Madias (Chief, Division of Nephrol-kidney (Fig. 6C) were larger than those in the trans-
ogy, New England Medical Center, Boston, Massachu-planted mouse kidney (Fig. 6D) [51].
setts): Thank you, Marc, for a fine presentation. TheInulin clearances of metanephroi transplanted into
number of nephrons in human kidneys is reported asrats expressed per 100 g body weight were very low
widely variable, and a reduced number of nephrons hascompared to normal in Sprague-Dawley rats of approxi-
been implicated in a predisposition to hypertension andmately the same size. However, kidneys are capable of
glomerulosclerosis. What events might be responsibleincreasing glomerular filtration considerably, even after
for such variability? Also, does modern biology offerall nephrons are formed. Single-nephron glomerular fil-
insights into the syndromes of renal hypoplasia, dyspla-tration rate in rats increases approximately 18-fold be-
sia, or agenesis?tween 22 and 60 days of life [53]. It is possible that over
Dr. Hammerman: There are a number of possible ex-time the rates of glomerular filtration of transplanted
planations for differences in nephron number. The moremetanephroi increase sufficiently so as to provide a level
we learn about nephrogenesis using animal models, theof renal function high enough to sustain life.
more explanations we have from which to choose. OneThe omentum is not an immunologically privileged
transgenic model that has taught us something aboutsite [52]. Therefore, the fact that developed kidneys
transplanted from one adult Sprague-Dawley rat to an- how nephrogenesis can go wrong is the Bcl-2 deficient
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Fig. 6. Photomicrographs of hematoxylin- and eosin-stained renal structures obtained four weeks after transplantation of mouse metanephroi
into kidneys of rats. (A) Interface (arrows) of transplanted mouse kidney and host kidney from non-CsA-treated rat. (B) Interface (arrows) of
transplanted mouse kidney and host kidney in a CsA-treated rat; “ca” shows calcified tubules. (C) Enlargement of a portion of host rat kidney;
glomeruli (G) and tubules (T) are shown. (D) Enlargement of a portion of mouse kidney; glomeruli (g) and tubules (t) are shown. Reprinted
with permission from Karger, Basel [51].
(Bcl-22/2) mouse [54]. Bcl-22/2 mice are born with the opening of a voltage-dependent cation channel in
the mitochondrial membrane that results in the releaseabout 50% of the nephrons present in kidneys of their
wild-type (WT) littermates. Their congenital renal hypo- of cytochrome c into the cytosol. Once in cytosol, cyto-
chrome c activates cellular proteases (caspases) that areplasia results from abnormal regulation of apoptosis dur-
ing renal development [55]. lethal for the cell [58]. The pro-apoptotic activity of Bax
is antagonized by Bcl-2, perhaps through the formationAt any given time, between 3% and 5% of cells in a
normally developing kidney are apoptotic [56]. Because of Bcl-2:Bax heterodimers [57].
Bcl-2 protein has been localized by immunohisto-apoptosis results in the rapid removal of cells by phago-
cytes, the presence of a few apoptotic cells can be indica- chemistry in developing kidney [59, 60]. Non-induced
metanephric blastemal cells undergo apoptosis [60]. Dur-tive of relatively large-scale programmed cell death. It
has been estimated that in the developing kidney, one ing the induction process for metanephric blastema,
upregulation of Bcl-2 protein is a relatively early event.cell dies for every 2 to 4 cells produced by division [56].
The existence of a predictable pattern of apoptosis dur- It would appear that, of the population of mesenchymal
cells that are committed to epithelial differentiation, onlying renal development indicates that this process is an
important one. Regulators of apoptosis in the kidney those cells expressing Bcl-2 subsequently differentiate
into renal epithelium. Therefore, the survival advantageand elsewhere include Bcl-2 and other members of the
Bcl-2 family of proto-oncogenes [54–57]. imparted by Bcl-2 gene expression is necessary for the
conversion of the uninduced mesenchyme into the ma-Bcl-2 protects cells against apoptosis [54]. The first
Bcl-2-associated family member to be identified was Bax, ture nephron [60].
In view of the pattern of expression for Bcl-2 in fetalwhich has partial amino acid sequence homology to Bcl-2
and which co-immunoprecipitates with Bcl-2 cell extracts kidney and its widespread ability to prevent apoptosis,
it is not surprising that mice deficient for Bcl-2 manifestand in vivo [57]. Bax promotes apoptosis by stimulating
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excessive apoptosis during renal development that re- were about 10% of normal, approximately the level
achieved by dialysis in humans [39]. Therefore, I believesults in congenital renal hypoplasia [55]. In contrast, mice
deficient for Bax (Bax2/2) have no gross abnormalities that a transplanted metanephros should be able to pro-
vide renal function adequate to sustain life.in renal development [57].
Several Bcl-2 family members regulate apoptosis in Dr. Harrington: Is IGF-I critical to the development
of the kidney? What about other growth factors?addition to Bcl-2 and Bax [54–60]. Also, there are many
regulators of apoptosis in addition to Bcl-2 family mem- Dr. Hammerman: Experiments utilizing metanephric
organ culture have shown that renal development inbers. Although Bcl-2 deficiency has never been reported
in humans, presumably such a condition would result in vitro depends on the expression of a number of growth-
promoting agents within the developing metanephros.a phenotype similar to that reported in Bcl-22/2 mice.
More subtle abnormalities in the regulation of pro- For example, blocking the expression or action of any
of the growth factors, transforming growth factor-agrammed cell death during renal development in hu-
mans, which theoretically could result from gene poly- (TGF-a), HGF, IGF-I, or IGF-II inhibits growth and
development in vitro [62]. Vascular endothelial growthmorphisms, mutations, or deletions involving Bcl-2,
Bcl-2 family members, or other regulators of apoptosis, factor is also produced by developing kidneys. Blocking
VEGF activity in vivo inhibits renal vascularization [63].might well translate into variability of nephron number.
In addition, it is possible that alterations in gene expres- Exposure of developing metanephroi to vitamin A stim-
ulates glomerulogenesis in vitro [64].sion and consequent reductions of nephron number re-
sult from environmental factors, such as maternal toxin In view of the growth factor requirements for renal
development in organ culture, it is somewhat surprisingexposure or poor nutrition.
Dr. Madias: Do knockout mice for the Bcl-2 gene that no abnormalities in renal development have been
reported in transgenic mice deficient for many of thesemanifest abnormalities in other organs?
Dr. Hammerman: Interestingly, the development of growth factors [65]. For example, mice that do not ex-
press IGF-I have normally developed kidneys at birthnon-renal organs in Bcl-22/2 mice is such that the ani-
mals, although slightly smaller than their WT littermates, [66]. Several possible explanations exist for the discrep-
ancies between the studies that utilize metanephric organare relatively normal at birth. During their first weeks
of life, the spleen and thymus undergo massive apoptotic culture and those that utilize transgenic mice. One expla-
nation is that redundancies among growth factors mightinvolution, and the mice exhibit premature graying of
hair [54]. Bcl-22/2 mice die within a month or two exist in renal development [66]. For example, the ab-
sence of IGF-I might be compensated for by anotherfollowing birth, with severe renal failure resulting from
polycystic kidney disease [61]. growth factor expressed in the developing kidney in vivo,
but not in the same way in vitro. Alternatively, a lackDr. John T. Harrington (Dean, Tufts University
School of Medicine, Boston, Massachusetts): Marc, what of IGF-I could be compensated for by a growth factor
present in the peripheral circulation in vivo, but not ingrowth factors would you expect to enhance the function
of transplanted metanephroi? vitro, where there is no circulation. In addition, a growth
factor present in the maternal circulation could effect aDr. Hammerman: The inulin clearances of the first
group of metanephroi we transplanted were very low. “maternal rescue” of a growth-factor-deficient embryo
[66].They were approximately 0.1 mL/min/100 g body weight,
or about 0.02% of that expected from a normal rat kidney A second explanation is that abnormalities in renal
development do indeed occur in the absence of IGF-I,[49]. Since that time, we have attempted to increase
clearances by incubating metanephroi in mixtures of but are not detectable in IGF I2/2 mice, most of which
die immediately after birth [66], because IGF-I is impor-growth factors prior to implantation and by administer-
ing growth factors to hosts. The growth factors chosen tant for that portion of renal development that occurs
within the nephrogenic zone after birth in rodents [4].for incubation or infusion were selected on the basis of
growth-promoting actions described for the factors in To address this question, we measured nephron numbers
in developed kidneys from IGF I2/2 mice that survived.metanephric organ culture [62]. For example, we have
administered hepatocyte growth factor (HGF), insulin- The IGF I2/2 mice were born with grossly normal kid-
neys. At 11 weeks after birth, the IGF I2/2 mice thatlike growth factor (IGF-I), IGF-II, and vascular endothe-
lial growth factor (VEGF) [63] in various ways and in survived were approximately 28% the weight of wild-
type littermates and had proportionally smaller kidneysvarying dosages. This has represented a lot of trial-and-
error type work. [66]. The number of nephrons per kidney was reduced
by approximately 20% in IGF I2/2 mice compared toWe have made considerable progress. The mean of
inulin clearances in a group of rats treated with growth WT littermates. Glomerular size also was reduced [66].
This is in contrast to the increased glomerular size (oligo-factors was 27 mL/min/100 g—almost 300 times the mean
in our first experiments. In some animals, clearances meganephronia) that is observed in Bcl-22/2 mice with
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reduced nephron numbers [61]. An increase in glomeru- velopmental state in vivo [61, 67]. Persistence of high
rates of proliferation of renal tubular cells is a featurelar size would be expected to result from the compensa-
tory growth that usually occurs in the setting of reduced of both animal models of renal cystic disease, including
the Bcl-22/2 mouse [61], and of ADPKD [67]. In addi-nephron number [10, 11].
Our findings indicate that IGF-I plays a role in de- tion, although rarely detected in the adult kidney, apo-
ptosis is easily detected in the walls of cysts and in thetermining nephron number and nephron size, perhaps
during the period of renal development that occurs in interstitium of kidneys in humans with ADPKD and in
animal models including the Bcl-22/2 mouse [61, 67].rodents for 1 to 2 weeks following birth. In humans,
IGF-I might increase nephron number during a compa- Polycystin is expressed during renal development in
mice [68] and in humans [69]. Evidence that it plays arable developmental stage during the third trimester of
pregnancy [66]. direct role in renal development comes from two types
of observations. First, mice with a PKD1 truncation mu-Dr. Harrington: Marc, you have told us about meta-
nephroi transplanted into the peritoneum. Where else tation that mimics a mutation found in ADPKD die
during the perinatal period with massively enlarged cys-might you be able to put them? Specifically, could you
transplant them into the old kidneys and have new kid- tic kidneys. That renal cyst formation in these mice be-
gins during embryonic day 15 in proximal tubules sug-neys grow?
Dr. Hammerman: The initial work we did involved gests that full-length polycystin is required for normal
renal development [70]. Second, the incubation of cul-the transplantation of metanephroi into the renal sub-
capsular space [49]. Metanephroi differentiate and grow tured metanephroi with peptides derived from the PKD
repeats of polycystin-1 results in an asymmetric patternif transplanted subcapsularly [45–47, 49]. Woolf et al
published evidence that, if transplanted into the nephro- of ureteric bud branching and a reduction in nephron
number [71].genic zone of a developing kidney, metanephroi are able
to filter [46, 47]. Unlike Woolf and colleagues, we trans- Regarding the use of metanephric transplantation to
study cystogenesis, I believe that the system might beplanted metanephroi into fully differentiated host kid-
neys. Interestingly, in our studies the collecting ducts of useful for such experiments. However, we have not yet
performed any.the transplanted metanephroi seemed to know where to
go, because they migrated down towards the renal papilla Dr. Madias: What might be the nature of tachyphy-
laxis to IGF-I that you observed when using high dosesof the host [49]. However, we could never establish that
any connections were made between the transplant and on a daily basis? Is there any information on changes
in bioavailability of systemically administered IGF-I orhost collecting systems. In addition, as the transplanted
metanephroi increased in size, they became constricted abundance of receptors in acute or chronic renal failure?
Dr. Hammerman: The basis for the tachyphylaxis toin the subcapsular space and developed an obstructed
phenotype [49]. the higher dose of IGF-I utilized in our previous study
is unclear. The interactions of IGF-I with sensitive tissuesDr. Harrington: What about transplanting the meta-
nephroi into the liver or any other organ? What I’m are complex [reviewed in 10, 11]. Insulin-like growth
factor-I circulates in tight noncovalent association withreally looking for is a site where there might be an endog-
enous source of growth factors to foster growth and binding proteins (IGFBPs), which both increase and in-
hibit IGF-I actions in vitro. In addition, IGFBPs in tissuesdevelopment of the metanephroi.
Dr. Hammerman: I’m afraid we have no data about regulate the interactions of circulating IGF-I with its
receptor. In kidney, the number of IGF-I receptors isthe liver or any other organ.
Dr. Ronald D. Perrone (Division of Nephrology, inversely related to levels of circulating IGF-I.
The pharmacokinetics of IGF-I in ESRD are largelyNew England Medical Center): Is polycystin involved in
the development of transplanted metanephroi? Would unaltered apart from a reduction in the total IGF-I vol-
ume of distribution. However, administration of IGF-Ithat be a suitable model for cystogenesis?
Dr. Hammerman: There is good reason to think that to patients with normal renal function or ESRD has been
accompanied by changes in at least one component of thepolycystin, the product of the PKD1 gene, plays a role
in renal development. Both the function of polycystin IGF-I effector system, a reduction in circulating levels of
IGFBP3 [38], a component of the complex to whichand the process of cyst development are incompletely
understood. However, abnormalities of processes that most circulating IGF-I is bound. Because the synthesis
of IGFBP3 is stimulated by growth hormone, the reduc-play key roles in renal development, cellular differentia-
tion, proliferation, and apoptosis are evident in renal tion in circulating IGFBP3 that accompanies IGF-I ad-
ministration is thought to result, at least in part, fromcystic disease. For example, cystic epithelial cells in kid-
neys from animals with inherited polycystic disease and inhibition of growth hormone release by exogenous
IGF-I [10, 11, 39].in humans with autosomal dominant polycystic kidney
disease (ADPKD) express markers of an immature de- Levels of IGFBP3 were reduced over time in patients
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who received 100 mg/kg IGF-I twice daily in our earlier please reflect on the relative importance of these ap-
proaches and comment on which ones in your judgmentstudy, as were levels of total circulating IGF-I [38], most
of which was presumably bound in a complex with should be pursued more vigorously?
Dr. Hammerman: One thing we have learned fromIGFBP3. In our later study, which employed a much
lower dosage of IGF-I, we found no reduction in the clinical studies testing whether IGF-I can prevent acute
renal failure or hasten recovery from established acutelevels of circulating IGF-I or IGFBP3 and no evidence
of tachyphylaxis over time [39]. It is possible that the renal failure is that many pitfalls exist in the design and
execution of investigations of this type. Each of the clini-lack of persistence of the action of IGF-I to increase
inulin clearance in our earlier study represented a refrac- cal studies that were performed were designed on the
basis of the use of IGF-I in rat models of ischemic acutetoriness that resulted directly from the change in
IGFBP3 or that was reflected by this change in IGFBP3. renal injury [16–18].
For a number of reasons, acute renal failure in humansDr. Andrew S. Levey (Division of Nephrology, New
England Medical Center): What growth factors are re- is more complex than ischemic renal injury in the rat.
Acute renal failure in humans usually occurs in the con-sponsible for compensatory renal hypertrophy?
Dr. Hammerman: I don’t know. I suspect that many text of multiple disparate and repeated insults to the
kidney and is often diagnosed in patients with multi-play a role [10, 11].
Dr. Madias: Rather than using the renal ablation organ dysfunction. In contrast, experimental acute ische-
mic injury in the rat typically is induced by a single periodmodel, have you transplanted metanephroi into rat mod-
els of glomerular or tubulointerstitial disease? Do the of renal artery clamping in an otherwise healthy young
animal [30].metanephroi grow in these settings?
Dr. Hammerman: We have not used such models. We had designed our study employing IGF-I or pla-
cebo immediately postoperatively in patients in whomDr. Andrew J. King (Division of Nephrology, New
England Medical Center): I would like to return to the renal blood flow was interrupted during surgery [29] to
be as similar as possible to experiments performed inissue relating to the variability of nephron number. Stud-
ies have shown that the amount of dietary protein influ- rats given IGF-I or vehicle beginning 30 minutes after
ischemia [16]. We hoped to be able to detect an ameliora-ences this process. When pregnant rats are given low-
protein diets, their offspring have decreased numbers of tive action on acute renal failure in humans if one existed,
as we did in rats. The strengths of our experimentalnephrons, whereas increased dietary protein results in
offspring with increased numbers of nephrons. Do you design were that we used a single center, Washington
University, a relatively uniform population of patients,have any further observations on this phenomenon?
Dr. Hammerman: As I mentioned, we have provided and a single group of vascular surgeons with whom we
had worked previously [29]. Based on previous experi-evidence for a role of IGF-I as a determinant of nephron
number [66]. It is interesting to note that the dominant ence, we thought we knew what the incidence of postop-
erative acute renal failure would be. Considering thisinfluence on fetal IGF-I levels in experimental animals
during the second half of pregnancy is the state of mater- information, we randomized what we thought to be an
appropriate number of patients. Fortunately for our pa-nal nutrition [72].
Dr. King: Does long-term administration of IGF-I in tients, but unfortunately for our study, the incidence of
acute renal failure postoperatively was much lower thanchronic renal failure confer histologic protection?
Dr. Hammerman: We have no data to address that that predicted from the previous experience of the surgi-
cal group [29]. Although we were able to show that IGF-Iissue.
Dr. Madias: If IGF-I were to be administered prior preserved renal function postoperatively, the lower-
than-expected incidence of acute renal failure preventedto ESRD, what would its effect be on intraglomerular
pressure? us from determining whether IGF-I was ameliorative for
acute renal failure in the clinical setting we employed.Dr. Hammerman: IGF-I does not induce hyperfiltra-
tion in rats. Micropuncture studies have shown that it Looked at in another way, there is little or no need to
use IGF-I to prevent acute renal failure after electivedilates both afferent and efferent arterioles. Glomerular
capillary pressures are not increased [13, 24]. surgery performed by a group of highly skilled surgeons
under normal conditions.Dr. Madias: In addition to IGF-I and other growth
factors, a number of other agents have been used in The observation in the rat model that provided the
rationale for the study designed to determine whetheranimal models of acute renal failure and found to offer
protection (for example, atrial natriuretic peptide, endo- IGF-I ameliorates established ARF [30] was that IGF-I
accelerates recovery from established ischemic injurythelin antagonists, ICAM-1 antibodies, aMSH, PAF an-
tagonists, anti-integrin peptides, antisense NOS oligonu- when administered as long as one day after the onset of
ischemia [17]. In contrast to the clinical trial we per-cleotides). This multitude of agents attests to the
complexity of the pathophysiology of ARF. Could you formed [29], the study testing the efficacy of IGF-I in
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established ARF was carried out in many different cen- been proposed to explain the beneficial effect of adminis-
tering cyclic RGD-containing peptides to ischemic ratsters and used a patient population with ARF resulting
from a variety of insults. Furthermore, patients had ARF [27, 73, 74]. In addition to being differentially expressed
in the distal nephron, beginning 2 to 3 days post ischemia,for as many as six days prior to receiving IGF-I or pla-
cebo [30]. This is a bit of a stretch considering that we osteopontin is also produced in the regenerating S3 seg-
ment along with one of its receptors, CD44 [74]. At thishad shown IGF-I to be effective when given one day
after ischemic injury in rats, and we had no information site and at this time following injury, the co-expression
of osteopontin and CD44 might serve a different purposeas to whether it would be effective after longer periods
of injury [17]. On the other hand, the ARF was well than it does in the distal nephron. I’ll tell you what I
think it is in a moment, but first I want to say a fewestablished after one day in the rat model, and if IGF-I
were the “magic bullet” for ARF, we might have ex- words about apoptosis during the process of tubular re-
generation following ischemic injury.pected it to work in humans after six days. The authors
of the multicenter trial recognize that if a more uniform Following induction of acute ischemic renal injury in
the rat, two peaks of apoptosis occur in regeneratingpopulation of patients had been enrolled in their trial,
and if the duration of ARF in enrollees had been shorter tubules. The first, smaller peak is maximal at three days
following injury [75]. Between days three and six post-(as in the rat model), IGF-I might have had a beneficial
effect [30]. If I had the opportunity to perform one addi- ischemia, the percentage of cells undergoing apoptosis
decreases. However, the incidence of apoptosis increasestional clinical study, I probably would test whether IGF-I
accelerates recovery when administered within a day or again on days 7 to 8, after which the incidence again
declines slowly over a period of weeks [75]. A burst oftwo of the onset of ARF.
We still need a medical therapy that will hasten recov- proliferative activity, as reflected by increased incorpora-
tion of 5-bromo 29-deoxyuridine (BrdU) into tubularery from established acute renal failure. Although the
rat model is an imperfect one, the process of recovery nuclei, occurs in the early phase of the regenerative re-
sponse. This proliferation results in a stratification offrom injury in the rat is sufficiently similar to what hap-
pens in humans, so that I believe that eventually the rat hyperplastic epithelial cells that is demonstrable two to
four days post injury and in a hyperplasia of circumferen-model will help us identify agents or design strategies
that will prove useful to patients. I would not be surprised tial epithelial cells with focal papillary proliferations that
are evident at 5 to 7 days [75]. Very few of the epithelialif one day we are able to show that IGF-I does have a
beneficial action in humans with established ARF when cells in the papillary projections or the circumferential
cells stain for BrdU on day 6 following injury. Therefore,administered under defined conditions. It may be that
its action is sufficient to make a difference in the rat, these projections originate from the initial overproduc-
tion of epithelial cells. The hyperplastic tubules are re-and in some settings in humans, but not in all patients
with established ARF. turned to their original cellularity, and papillary prolifer-
ations are remodeled through a wave of apoptosis thatFor now, we need to learn more about the cellular and
molecular events that mediate the regenerative process. I is reflected by second peak [75].
In addition to playing a role in renal development,spoke briefly about the phenomenon of preconditioning
[31, 32] and how IGF-I administered prior to injury might Bcl-2 family members appear to regulate apoptosis fol-
lowing acute renal injury. An increase in levels of renalact as a preconditioner in the rat model [17]. To identify
agents that might participate in recovery, we have identi- Bcl-2 mRNA occurs within 24 hours of ischemic injury
in the rat. The levels of Bcl-2 mRNA remain elevatedfied genes that are expressed differentially in the kidney
post ischemia in rats that receive IGF-I or vehicle prior to for three days but return to baseline by day five post-
ischemia. The increased expression of Bcl-2 mRNA andinjury [27]. The first gene that we found to be expressed
differentially under these conditions codes for osteopon- protein is localized to regenerating proximal tubule cells
relining the basement membrane [76]. Normal epithelialtin [27]. The finding three years later by Noiri et al that
mice with a targeted disruption of the osteopontin gene cells undergo apoptosis when the cells are detached from
their underlying matrix. Apoptosis that occurs in thishave reduced tolerance to acute ischemic renal injury
relative to their WT littermates [73] validates the utility setting is designated anoikis [77]. It occurs during cell
migration, such as that required for relining of the de-of our approach.
It is interesting that in vehicle-treated rats, osteopontin nuded proximal tubule basement membrane following
acute renal injury [78]. The first wave of apoptosis in theis expressed early following ischemia in the distal tubule
and medullary thick ascending limb of Henle’s loop. At proximal tubule following acute ischemic injury might
reflect anoikis of cells that have lost, and are in thethese distal sites, osteopontin might inhibit aggregation
of sloughed proximal tubule cells by occupying integrin process of reforming, cell-cell contacts during migration.
The expression of Bcl-2 in regenerating tubules duringbinding sites through its intrinsic arginine-glycine-aspar-
tic acid (RGD) sequence. Such a means of action has migration could limit the extent of apoptosis during this
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